Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Capricor Therapeutics Inc (CAPR)

NASDAQ
Currency in USD
Disclaimer
5.300
-0.120(-2.21%)
Closed
After Hours
5.260-0.040(-0.755%)

CAPR Comments

Price Target 50$
Bravo
The clinical trials news seemed good, but the stock got hit hard. Any ideas for today? Thanks.
$10, $Capr has Cap $60M, Contract $705M, Capricor will receive an upfront payment of $30 million with potential additional milestone payments of up to $705 million.
nevermind
buy
should buy?
This is a company that leaves investors without any news or updates. Linda mentions FDA approval "Soon" which is years. Linda was mentioning about her Cap 1002 for the past years and repeats the same garbage over and over. They are not doing nothing.
Does anyone know when the clinical news is supposed to be released?
Will be some news tomorrow afternoon at 4.30
Where do we go from here?
Up up and away!!!! Gonna be a fun couple of weeks
down and under !
where is CAPR headed?
prediction for eom?
it should go to 12-14 by August 2nd week.
still ???
We will head to 20$-30$ once PR is released
which PR ??
Today capr into 9 dollars
💝
have any good news?
http://worldnewsnetwork.co.in/amanda-kloots-shares-hopeful-health-update-on-husband-nick-cordero-daily-mail/
Hold long
 Thanks Richard. However, the premarket's +30% flew away so quickly. It'd have been nice.
Trust me this is cheap, catch it before it hits 20$ in a few months.
 God hears you.
Prepare to ride the wave as of today.
Cap 1002 meets FDA’s definition for accelerated approval: There is no other drug in the space for non-ambulant boys other than steroids. P2 Data is meaningful. It’s a drug with good safety profile (given to over 150 patients). A P3 trial would take yrs in a terminal condition. From fda website on Accelerated Approval: “In some cases, the approval of a new drug is expedited. Accelerated Approval can be applied to promising therapies that treat a serious or life-threatening condition and provide therapeutic benefit over available therapies. This approach allows for the approval of a drug that demonstrates an effect on a “surrogate endpoint” that is reasonably likely to predict clinical benefit, or on a clinical endpoint that occurs earlier but may not be as robust as the standard endpoint used for approval. This approval pathway is especially useful when the drug is meant to treat a disease whose course is long, and an extended period of time is needed to measure its effect.”
This will go down to 4 or 5. The wait will be long for news.
I guess I was right. The stock should turn around soon, I cant wait.
Benefiting from coronavirus, its share price will possibly gap up after releasing its financial statements today
Good news!! Cedars-Sinnai doctors treat Coronavirus with lab-grown human heart cells, known as CAP-2000 from the biotechnology company Capricor Therapeutics https://www.dailynews.com/2020/05/12/cedars-sinai-doctors-treat-coronavirus-with-lab-grown-human-heart-cells/
The fact that 100 percent survival was in critical COVID 19 patients for over one month trial is amaing news!! http://irdirect.net/prviewer/release/id/4306152
Must prove it works at scale.
will it drop back to $2.00? most likely
70% bullish - after a pump and attempt to dump - what are people thinking?
corona pan or corona bluff ?
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.